For the year ending 2025-12-31, SNDX has $529,706K in assets. $465,076K in debts. $134,930K in cash and cash equivalents.
| Balance Sheets | 2025-12-31 | |||
|---|---|---|---|---|
| Cash and cash equivalents | 134,930 | |||
| Short-term investments | 259,140 | |||
| Accounts receivable, net | 37,996 | |||
| Inventory, net | 32,754 | |||
| Short-term deposits | 19,616 | |||
| Other receivables, net | 6,404 | |||
| Collaboration receivable, net | 23,745 | |||
| Prepaid expenses and other current assets | 13,496 | |||
| Total current assets | 528,081 | |||
| Long-term investments | 0 | |||
| Property and equipment, gross | 606 | |||
| Accumulated depreciation | 425 | |||
| Property and equipment, net | 181 | |||
| Right-of-use asset | 1,342 | |||
| Restricted cash | 102 | |||
| Total assets | 529,706 | |||
| Accounts payable | 16,580 | |||
| Collaboration payable, net | 0 | |||
| Accrued expenses and other current liabilities | 103,064 | |||
| Current portion of royalty interest financing | 0 | |||
| Current portion of right-of-use liability | 470 | |||
| Current portion of capital lease | 2 | |||
| Total current liabilities | 120,116 | |||
| Royalty interest financing, less current portion | 343,909 | |||
| Right-of-use liability, less current portion | 1,051 | |||
| Total long-term liabilities | 344,960 | |||
| Total liabilities | 465,076 | |||
| Common stock, 0.0001 par value, 200,000,000 shares authorized at december 31, 2025 and december 31, 2024, respectively 87,405,979 and 85,694,443 shares outstanding at december 31, 2025 and december 31, 2024, respectively | 9 | |||
| Additional paid-in capital | 1,570,749 | |||
| Accumulated other comprehensive income | 452 | |||
| Accumulated deficit | -1,506,580 | |||
| Total stockholders' equity | 64,630 | |||
| Total liabilities and stockholders' equity | 529,706 | |||
Syndax Pharmaceuticals Inc (SNDX)
Syndax Pharmaceuticals Inc (SNDX)